Latest news
Funding & Finance
Evotec Appoints Dr Ingrid Müller as Chief Operating Officer
Evotec has announced the appointment of Dr Ingrid Müller as Chief Operating Officer (COO). Dr Müller will be joining Evotec’s Management Board, effective 1...
Drug Discovery & Development
Renaissance Pharma secures FDA Fast Track Designation and IND clearance for Daretabart in high-risk neuroblastoma
The US Food and Drug Administration (FDA) has granted Fast Track Designation for Daretabart (hu1418K322A), a novel anti-GD2 monoclonal antibody in development for the...
Clinical Trials Insights
AbbVie’s Elahere succeeds in phase 2 platinum-sensitive ovarian cancer trial
AbbVie has announced that late-breaking results from the phase 2 IMGN853-0420 trial.
The study evaluated the potential efficacy and safety of mirvetuximab soravtansine-gynx, a first-in-class antibody-drug...
Pharma in Healthcare
Cell line development market to reach $8.95 billion by 2031 with Gene & Cell Therapy manufacturing growing at 10.88%
According to Mordor Intelligence, the global cell line development market is projected to grow from USD 4.97 billion in 2025 to USD 5.48 billion in 2026, and is expected to...
Events and Conferences
Global Drug Delivery and Formulation (DDF) Summit
18-20 May Berlin, Germany
The Global Drug Delivery and Formulation (DDF) Summit is Europe’s premier gathering for professionals at the forefront of pharmaceutical development and drug delivery...
Events and Conferences
Chemspec Europe reveals new details about 2026 conference programme
6–7 May 2026 Koln, Germany
Chemspec Europe has unveiled further details of its highly anticipated conference programme, offering attendees fresh insight into the key...
Drug Discovery & Development
Oragenics doses first patient in phase 2a clinical trial of drug for mild traumatic brain injury
Oragenics, a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, has announced that the first patient has been dosed in its...
Drug Discovery & Development
Bracco invests in GMP manufacturing facility for cell therapy products
Bracco Imaging, a global pharmaceutical company that develops, manufactures, and markets innovative healthcare solutions, announced an upgrade of its manufacturing site in Geneva to...
Drug Discovery & Development
Virica Biotech and Fujifilm Biosciences collaborate to develop production enhancers
Virica Biotech, a cell enhancer company specialising in Viral Sensitizers for viral vector manufacturing, has announced receipt of advisory services and funding from the...
Funding & Finance
Novartis agrees to acquire Excellergy, building on allergy leadership with next-generation anti-IgE innovation
Novartis has announced that it has entered into an agreement to acquire Excellergy, a private biotech company developing next-generation anti-IgE therapies for IgE-driven diseases....
Funding & Finance
Evotec to receive around $100 Million as part of Tubulis acquisition
Evotec SE has announced that it is expected to receive approximately $100 million in upfront consideration upon closing of the sale of Tubulis GmbH...
Funding & Finance
Thermo Fisher collaborates with HealthVerity to expand real-world data capabilities
Thermo Fisher Scientific, the world leader in serving science, has announced a strategic data collaboration with HealthVerity, a leading real-world data (RWD) marketplace, to...
Drug Discovery & Development
FDA approves new high dose regimen of Spinraza (nusinersen) for spinal muscular atrophy
Biogen has announced that the high dose regimen of Spinraza® (nusinersen), which is comprised of 50 mg/5 mL and 28 mg/5 mL doses, has been approved...
Drug Discovery & Development
Apotex receives first US FDA tentative approval for a generic version of Ozempic (semaglutide injection)
Apotex has announced it has received the first US Food and Drug Administration (FDA) Tentative Approval for its Abbreviated New Drug Application (ANDA) for...
Drug Discovery & Development
Lynk Pharmaceuticals announces NDA acceptance for zemprocitinib
Lynk Pharmaceuticals, a clinical-stage innovative drug development company focused on therapies for immune and inflammatory diseases, has announced that the New Drug Application (NDA)...
Clinical Trials Insights
MetaVia doses the first patient in higher-dose phase 1 study of DA-1726, Its GLP-1 and glucagon dual agonist for the treatment of obesity
MetaVia, a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, has announced that the first patient has been dosed in part 3 of its...
- Advertisement -
- Advertisement -
- WVCD Ad -
- Advertisement -
MOST POPULAR POSTS
© 2026 Pharma Press Publishing.